Loading...
Market
What will be the percentage increase in Korro Bio's stock price by end of 2024?
3
Resolution / Starting Odds
Less than 50% • 25%
50% to 100% • 25%
101% to 150% • 25%
More than 150% • 25%
Stock market data and financial news outlets
Story
Wave Life Sciences Achieves First Human RNA Editing in AATD Trial, Shares Surge 75%
Oct 16, 2024, 03:26 PM
Wave Life Sciences announced that it has achieved the first-ever therapeutic RNA editing in humans in its RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD). A single subcutaneous dose—the first and lowest dose tested—of WVE-006 in patients with homozygous “ZZ” AATD resulted in mean plasma total AAT levels of approximately 11 micromolar, with mean wild-type M-AAT representing 6% of normal levels. This milestone, achieved after over 10 years of oligonucleotide innovation at Wave, validates RNA editing as a therapeutic approach and demonstrates the company's innovative chemistry. Following the announcement, shares of Wave Life Sciences surged by up to 75%. Other companies in the RNA editing field, including ProQR Therapeutics and Korro Bio, also experienced significant stock price increases, with ProQR up 75% and Korro Bio up 126%. Additionally, GSK increased its stake in Wave Life Sciences by purchasing 2.8 million shares at $8 per share.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease • 25%
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
Above 30% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
